Cargando…

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations

BACKGROUND: A retrospective analysis verified the role of gene mutations in brain metastasis in patients with non‐small cell lung cancer (NSCLC). METHODS: Data from 552 patients with advanced NSCLC treated from January 2015 to June 2017 in the Affiliated Cancer Hospital of Zhengzhou University were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Huijuan, Wang, Ziqi, Zhang, Guowei, Zhang, Mina, Zhang, Xiaojuan, Li, Haixia, Zheng, Xuanxuan, Ma, Zhiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970058/ https://www.ncbi.nlm.nih.gov/pubmed/31769228 http://dx.doi.org/10.1002/cam4.2706

Ejemplares similares

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations
por: ZHANG, Guowei, et al.
Publicado: (2022)

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
por: Ferreira, Daniela, et al.
Publicado: (2021)

Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()
por: Zhao, Chao, et al.
Publicado: (2014)

RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis
por: Wu, Min, et al.
Publicado: (2022)

RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer
por: Sasaki, Hidefumi, et al.
Publicado: (2012)

EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer
por: DONG, YU, et al.
Publicado: (2016)

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
por: Wang, Jinguang, et al.
Publicado: (2018)

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report
por: Zhao, Zichen, et al.
Publicado: (2022)

Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis
por: Zhang, Chengkai, et al.
Publicado: (2023)

Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study
por: Wang, Huijuan, et al.
Publicado: (2023)

Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study
por: Yan, Xiangtao, et al.
Publicado: (2018)

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
por: Zhang, Guowei, et al.
Publicado: (2017)

Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
por: Qiao, Meng, et al.
Publicado: (2020)

A Screening Method for the ALK Fusion Gene in NSCLC
por: Murakami, Yoshiko, et al.
Publicado: (2012)

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
por: Wang, Wenxian, et al.
Publicado: (2016)

Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
por: Zeng, Hao, et al.
Publicado: (2019)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations
por: Dugay, Frédéric, et al.
Publicado: (2017)

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022)

SKA3 promotes lung adenocarcinoma metastasis through the EGFR–PI3K–Akt axis
por: Hu, Dan-dan, et al.
Publicado: (2020)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer
por: Theard, Patricia L, et al.
Publicado: (2020)

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China
por: Li, Tao, et al.
Publicado: (2023)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC
por: Xie, Tongji, et al.
Publicado: (2023)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
por: Tan, Xueyun, et al.
Publicado: (2022)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

Therapeutic Sequencing in ALK(+) NSCLC
por: Elsayed, Mei, et al.
Publicado: (2021)

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC
por: Yang, Haitao, et al.
Publicado: (2017)

Targeting SLMAP-ALK—a novel gene fusion in lung adenocarcinoma
por: Pagan, Carlos, et al.
Publicado: (2019)

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway
por: Hou, Xiaoying, et al.
Publicado: (2018)

Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients
por: Novaes, Lázaro Antonio Campanha, et al.
Publicado: (2021)

Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Zhang, Quxia, et al.
Publicado: (2018)

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
por: Wang, Chunyue, et al.
Publicado: (2022)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lnf32rfekb9bsrl3ao6e3qg9qd